P450 2C18 catalyzes the metabolic bioactivation of phenytoin

Chemical Research in Toxicology

Volumn 18, Issue 12, 2005, Pages 1868-1875

  Kinobe, Robert T ^a   Parkinson, Oliver T ^a   Mitchell, Deanne J ^a   Gillam, Elizabeth M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; CATECHOL; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; PHENYTOIN; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; AUTOOXIDATION; CATALYSIS; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVATION; DRUG HYPERSENSITIVITY; DRUG PROTEIN ADDUCT; DRUG PROTEIN BINDING; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; MALE; METABOLIC ACTIVATION; NONHUMAN; NORMAL HUMAN; RAT; TISSUE SPECIFICITY;

ANIMALS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYSIS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; HUMANS; HYDROXYLATION; KINETICS; MALE; MICROSOMES, LIVER; PHENYTOIN; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 29644445409     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050181o     Document Type: Article

References (44)

1. Tennis P., and Stern R. S. (1997) Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study. Neurology 49, 542-546.
2. Haruda, F. (1997) Phenytoin hypersensitivity: 38 cases. Neurology 29, 1480-1485.
3. Park, B. K., Coleman, J. W., and Kitteringham, N. R. (1987) Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 36, 581-590.
4. Munns, A. J., DeVoss, J. J., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (1997) Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 10, 1049-1058.
5. Spielberg, S. P., Gordon, G. B., Blake, D. A., Goldstein, D. A., and Herlong, H. F. (1981) Predisposition to phenytoin hypersensitivity assessed in vitro. N. Engl. J. Med. 305, 722-727.
6. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (2000) Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 28, 945-950.
7. Veronese, M. E., Mackenzie, P. I., Doecke, C. J., McManus, M. E., Miners, J. O., and Birkett D. J. (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175, 1112-1118.
8. Bajpai, M., Roskos, L. K., Shen, D. D., and Levy, R. H. (1996) Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos. 24, 1401-1403.
9. Komatsu, T., Yamazaki, H., Asahi, S., Gillam, E. M. J., Guengerich, F. P., Nakajima, M., and Yokoi, T. (2000) Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab. Dispos. 28, 1361-1368.
10. Guengerich, F. P. (1994) Analysis and characterization of enzymes. In Principles and Methods of Toxicology (Hayes, A. W., Ed.) 3rd ed., pp 1259-1313, Raven Press, Ltd., New York.
11. Parikh, A., Gillam, E. M. J., and Guengerich, F. P. (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnol. 15, 784-788.
12. Shimada, T., Wunsch, R. M., Hanna, I. H., Sutter, T. R., Guengerich, F. P., and Gillam, E. M. J. (1998) Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch. Biochem. Biophys. 357, 111-120.
13. Gillam, E. M. J., Aguinaldo, A. M., Notley, L. M., Kim, D., Mundkowski, R. G., Volkov, A. A., Arnold, F. H., Soucek, P., DeVoss, J. J., and Guengerich, F. P. (1999) Formation of indigo by recombiaant mammalian cytochrome P450s. Biochem. Biophys. Res. Commun. 265, 467-472.
14. Gillam, E. M. J., Ueng, Y.-F., Wunsch, R. M., Shimada, T., Kamataki, T., and Guengerich, F. P. (1997) Expression of cytochrome P450 3A7 in Escherichia coli: Effects of 5′ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 346, 81-90.
15. Hanna, I. H., Reed, J. R., Guengerich, F. P., and Hollenberg, P. F. (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression levels in human liver. Arch. Biochem. Biophys. 376, 206-216.
16. Richardson, T. H., Jung, F., Griffin, K. J., Wester, M., Raucy, J. L., Kemper, B., Bornheim, L. M., Hassett, C., Omiecinski, C. J., and Johnson, E. F. (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch. Biochem. Biophys. 323, 87-96.
17. Gillam, E. M. J., Baba, T., Kim, B.-R., Ohmori, S., and Guengerich, F. P. (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123-131.
18. Notley, L. M., de Wolf, C. J. F., Wunsch, R. M., Lancaster, R. G., and Gillam, E. M. J. (2002) Bioactivation of Tamoxifen by recombinant human cytochrome P450 Enzymes. Chem. Res. Toxicol. 15, 614-622.
19. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378.
20. Yasukochi, Y., and Masters, B. S. S. (1976) Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251, 5337-5344.
21. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 243, 1331-1332.
22. m values: Implications for clinical correlation. J. Pharmacol. Exp. Ther. 282, 391-396.
23. Carlile, D. J., Hakooz, N., M. K. B., and Houston, J. B. (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharmacol. 47, 625-635.
24. Tang, C., Lin, Y., Rodrigues, A. D., and Lin, J. H. (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: An impact more than protein binding. Drug Metab. Dispos. 30, 648-654.
25. Dickinson, R. G., Hooper, W. D., Patterson, M., Eadie, M. J., and Maguire, B. (1985) Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther. Drug Monit. 7, 283-289.
26. Richens, A. (1979) Clinical pharmacokinetics of phenytoin. Clin. Pharmacokinet. 4, 153-169.
27. Lund, L., Berlin, A., and Lunde, K. M. (1972) Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clin. Pharmacol. Ther. 13, 196-200.
28. McLure, J. A., Miners, J. O., and Birkett, D. J. (2000) Nonspecific binding of drugs to human liver microsomes. Br. J. Clin. Pharmacol. 49, 453-461.
29. Worboys, P. D., Bradbury, A., and Houston, J. B. (1997) Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metab. Dispos. 25, 460-467.
30. Yamazaki, H., and Shimada, T. (1999) Effect of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 29, 231-241.
31. Guengerich, F. P., Gillam, E. M. J., and Shimada, T. (1996) New applications of bacterial systems to problems in toxicology. Crit. Rev. Toxicol. 26, 551-583.
32. Gillam, E. M. J. (1998) Human cytochrome P450 enzymes expressed in bacteria: Reagents to probe molecular interactions in toxicology. Clin. Exp. Pharmacol. Physiol. 25, 877-886.
33. Yamazaki, H., Gillam, E. M. J., Dong, M.-S., Johnson, W. W., Guengerich, F. P., and Shimada T. (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: Effects of cytochrome p450-P450 and cytochrome P450-b5 interactions. Arch. Biochem. Biophys. 342, 329-337.
34. Giancarlo, G. M., Venkatakrishnan, K., Granda, B. W., von Moltke, L. L., and Greenblatt, D. J. (2001) Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 57, 31-36.
35. Liu, K. H., Kim, M. J., Jung, W. M., Kang, W., and Cha, J. G. (2004) Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab. Dispos. 33, 209-213.
36. Furuya, H., Meyer, U. A., Gelboin, H. V., and Gonzalez, F. J. (1991) Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol. Pharmacol. 40, 375-382.
37. Richardson, T. H., Griffin, K. J., Jung, F., Raucy, J. L., and Johnson, E. F. (1997) Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch. Biochem. Biophys. 338, 157-164.
38. Zaphiropoulos, P. G. (1997) Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol. Cell. Biol. 17, 2985-2993.
39. Mace, K., Bowman, E. D., Vautravers, P., Shields, P. G., Harris, C. C., and Pfeifer, A. M. (1998) Characterisation of xenobiotic-metabolising enzyme expression inhuman bronchial mucosa and peripheral lung tissues. Eur. J. Cancer 34, 914-920.
40. Klose, T. S., Blaisdell, J. A., and Goldstein, J. A. (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. 13, 289-295.
41. Guengerich, F. P. (1995) Human cytochrome P450 enzymes. In Cytochrome P450 (Ortiz de Montellano, P. R., Ed.) 2nd ed., pp 473-535, Plenum Press, New York.
42. Fritz, S., Lindner, W., Roots, I., Frey, B. M., and Kupfer, A. (1987) Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J. Pharmacol. Exp. Ther. 241, 615-622.
43. Ieiri, I., Mamiya, K., Urae, A., Wada, Y., Kimura, M., Irie, S., Amamoto, T., Kubota, T., Yoshioka, S., Nakamura, K., Nakano, S., Tashiro, N., and Higuchi, S. (1997) Stereoselective 4′-hydroxylation of phenytoin: Relationship to (S)-mephenytoin polymorphism in Japanese. Br. J. Clin. Pharmacol. 43, 441-445.
44. Yasumori, T., Chen, L. S., Li, Q. H., Ueda, M., Tsuzuki, T., Goldstein, J. A., Kato, R., and Yamazoe, Y. (1999) Human CYP2C-mediated Stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem. Pharmacol. 57, 1297-1303.